Securities ▲▼ | Shares | Value ($K) | |||||
|---|---|---|---|---|---|---|---|
Q3 2023 ▲▼ | Q4 2023 ▲▼ | Change ▲▼ | Q3 2023 ▲▼ | Q4 2023 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Pharvaris N.V. COM | 3,743,450 | 4,038,842 | +295,392 | 78,126 | 113,290 | 57.25% | +35,164 |
| Kura Oncology, Inc.(KURA) | 1,849,947 | 1,849,947 | 0 | 16,872 | 26,602 | 13.44% | +9,731 |
| Kinnate Biopharma Inc. | 9,671,643 | 9,671,643 | 0 | 13,540 | 22,922 | 11.58% | +9,381 |
| Syndax Pharmaceuticals, Inc.(SNDX) | 875,000 | 875,000 | 0 | 12,705 | 18,909 | 9.56% | +6,204 |
| Lyell Immunopharma, Inc. | 8,784,813 | 8,325,000 | -459,813 | 12,914 | 16,151 | 8.16% | +3,237 |
| Aclaris Therapeutics, Inc.(ACRS) | 2,808,034 | 0 | -2,808,034 | 19,235 | 0 | — | -19,235 |
| Cymabay Therapeutics, Inc. | 1,787,094 | 0 | -1,787,094 | 26,646 | 0 | — | -26,646 |